Annual EBIT
-$19.83 M
+$90.83 M+82.08%
December 1, 2024
Summary
- As of March 13, 2025, FULC annual earnings before interest & taxes is -$19.83 million, with the most recent change of +$90.83 million (+82.08%) on December 1, 2024.
- During the last 3 years, FULC annual EBIT has risen by +$61.22 million (+75.53%).
- FULC annual EBIT is now at all-time high.
Performance
FULC EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$19.43 M
+$3.63 M+15.76%
December 31, 2024
Summary
- As of March 13, 2025, FULC quarterly earnings before interest & taxes is -$19.43 million, with the most recent change of +$3.63 million (+15.76%) on December 31, 2024.
- Over the past year, FULC quarterly EBIT has increased by +$8.56 million (+30.59%).
- FULC quarterly EBIT is now -137.01% below its all-time high of $52.49 million, reached on June 30, 2024.
Performance
FULC Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$19.83 M
+$8.56 M+30.15%
December 31, 2024
Summary
- As of March 13, 2025, FULC TTM earnings before interest & taxes is -$19.83 million, with the most recent change of +$8.56 million (+30.15%) on December 31, 2024.
- Over the past year, FULC TTM EBIT has increased by +$90.83 million (+82.08%).
- FULC TTM EBIT is now -171.33% below its all-time high of -$7.31 million, reached on March 31, 2018.
Performance
FULC TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
FULC EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +82.1% | +30.6% | +82.1% |
| 3 y3 years | +75.5% | +30.6% | +82.1% |
| 5 y5 years | +76.5% | +30.6% | +82.1% |
FULC EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +82.3% | -137.0% | +43.3% | at high | +82.6% |
| 5 y | 5-year | at high | +82.3% | -137.0% | +43.3% | at high | +82.6% |
| alltime | all time | at high | +82.3% | -137.0% | +47.8% | -171.3% | +82.6% |
Fulcrum Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | - | -$19.43 M(-15.8%) | -$19.83 M(-30.2%) |
| Dec 2024 | -$19.83 M(-82.1%) | - | - |
| Sep 2024 | - | -$23.06 M(-143.9%) | -$28.40 M(-13.4%) |
| Jun 2024 | - | $52.49 M(-275.9%) | -$32.77 M(-70.9%) |
| Mar 2024 | - | -$29.83 M(+6.6%) | -$112.56 M(+1.7%) |
| Dec 2023 | -$110.66 M(-1.3%) | -$27.99 M(+2.0%) | -$110.66 M(-0.0%) |
| Sep 2023 | - | -$27.44 M(+0.5%) | -$110.68 M(+3.3%) |
| Jun 2023 | - | -$27.29 M(-2.3%) | -$107.13 M(-6.1%) |
| Mar 2023 | - | -$27.94 M(-0.3%) | -$114.08 M(+1.7%) |
| Dec 2022 | -$112.13 M(+38.3%) | -$28.01 M(+17.2%) | -$112.13 M(+4.1%) |
| Sep 2022 | - | -$23.89 M(-30.2%) | -$107.68 M(+3.0%) |
| Jun 2022 | - | -$34.23 M(+31.7%) | -$104.56 M(+16.2%) |
| Mar 2022 | - | -$26.00 M(+10.4%) | -$90.01 M(+11.0%) |
| Dec 2021 | -$81.05 M | -$23.56 M(+13.4%) | -$81.05 M(+7.7%) |
| Sep 2021 | - | -$20.77 M(+5.5%) | -$75.28 M(+2.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$19.68 M(+15.5%) | -$73.62 M(+5.4%) |
| Mar 2021 | - | -$17.04 M(-4.2%) | -$69.86 M(-2.4%) |
| Dec 2020 | -$71.61 M(-15.0%) | -$17.79 M(-6.9%) | -$71.61 M(+1.8%) |
| Sep 2020 | - | -$19.10 M(+20.0%) | -$70.31 M(+3.1%) |
| Jun 2020 | - | -$15.92 M(-15.3%) | -$68.22 M(+3.7%) |
| Mar 2020 | - | -$18.80 M(+14.0%) | -$65.79 M(-21.9%) |
| Dec 2019 | -$84.22 M(+151.4%) | -$16.49 M(-3.0%) | -$84.22 M(+9.4%) |
| Sep 2019 | - | -$17.01 M(+26.0%) | -$76.98 M(+11.5%) |
| Jun 2019 | - | -$13.49 M(-63.8%) | -$69.06 M(+8.9%) |
| Mar 2019 | - | -$37.23 M(+302.4%) | -$63.41 M(+89.3%) |
| Dec 2018 | -$33.50 M(+45.7%) | -$9.25 M(+1.8%) | -$33.50 M(+38.2%) |
| Sep 2018 | - | -$9.09 M(+15.8%) | -$24.25 M(+60.0%) |
| Jun 2018 | - | -$7.85 M(+7.4%) | -$15.16 M(+107.4%) |
| Mar 2018 | - | -$7.31 M | -$7.31 M |
| Dec 2017 | -$22.99 M | - | - |
FAQ
- What is Fulcrum Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics annual EBIT year-on-year change?
- What is Fulcrum Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics quarterly EBIT year-on-year change?
- What is Fulcrum Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics TTM EBIT year-on-year change?
What is Fulcrum Therapeutics annual earnings before interest & taxes?
The current annual EBIT of FULC is -$19.83 M
What is the all time high annual EBIT for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high annual earnings before interest & taxes is -$19.83 M
What is Fulcrum Therapeutics annual EBIT year-on-year change?
Over the past year, FULC annual earnings before interest & taxes has changed by +$90.83 M (+82.08%)
What is Fulcrum Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of FULC is -$19.43 M
What is the all time high quarterly EBIT for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high quarterly earnings before interest & taxes is $52.49 M
What is Fulcrum Therapeutics quarterly EBIT year-on-year change?
Over the past year, FULC quarterly earnings before interest & taxes has changed by +$8.56 M (+30.59%)
What is Fulcrum Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of FULC is -$19.83 M
What is the all time high TTM EBIT for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high TTM earnings before interest & taxes is -$7.31 M
What is Fulcrum Therapeutics TTM EBIT year-on-year change?
Over the past year, FULC TTM earnings before interest & taxes has changed by +$90.83 M (+82.08%)